Gefimipsa 250mg Capsule
Prescription Required
Product introduction
Gefimipsa 250mg Capsule is used in the treatment of non-small cell lung cancer. It is used in patients in which it has spread to other parts of the body, who have abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer.
Gefimipsa 250mg Capsule is used to treat different types of cancer
Gefimipsa 250mg Capsule is used to treat different types of cancer
Uses of Gefimipsa Capsule
Benefits of Gefimipsa Capsule
In Non-small cell lung cancer
Non-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Gefimipsa 250mg Capsule helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.
Side effects of Gefimipsa Capsule
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if youβre worried about them
Common side effects of Gefimipsa
- Diarrhea
- Dry skin
- Loss of appetite
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weakness
- Weight loss
How to use Gefimipsa Capsule
Take this medicine in the dose and duration as advised by your doctor. Gefimipsa 250mg Capsule may be taken with or without food, but it is better to take it at a fixed time.
Safety advice
Alcohol
UNSAFE
It is unsafe to consume alcohol with Gefimipsa 250mg Capsule.
Pregnancy
CONSULT YOUR DOCTOR
Gefimipsa 250mg Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
Breast feeding
CONSULT YOUR DOCTOR
Gefimipsa 250mg Capsule is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Driving
UNSAFE
Gefimipsa 250mg Capsule may cause side effects which could affect your ability to drive.
Gefimipsa 250mg Capsule may make you feel weak. This may affect your driving ability.
Gefimipsa 250mg Capsule may make you feel weak. This may affect your driving ability.
Kidney
CAUTION
Gefimipsa 250mg Capsule should be used with caution in patients with severe kidney disease. Dose adjustment of Gefimipsa 250mg Capsule may be needed. Please consult your doctor.
Liver
SAFE IF PRESCRIBED
Gefimipsa 250mg Capsule is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Gefimipsa 250mg Capsule may not be needed in these patients. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
No substitutes found for this medicine
Quick tips
- Gefimipsa 250mg Capsule helps treat non-small cell lung cancer that is locally advanced, or has spread to other areas of the body.
- Take it with or without food, preferably at the same time each day.
- Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after taking this medicine.
- Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn't stop or if you find blood in your stools.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.
- Inform your doctor if you develop ulceration in your mouth, changes in your vision or if you experience a worsening cough, shortness of breath, or breathing difficulties while taking this medicine.
- Your doctor may want you to have regular blood tests to monitor your liver function while you are having treatment with this medicine.
Fact Box
Chemical Class
Quinazolinamines
Habit Forming
No
Therapeutic Class
ANTI NEOPLASTICS
Action Class
Tyrosine kinase inhibitors
Patient concerns
User feedback
Patients taking Gefimipsa 250mg Capsule
Once A Day
94%
Twice A Day
6%
What are you using Gefimipsa Capsule for?
Others
50%
Small cell lu*
25%
Non-small cel*
25%
*Small cell lung cancer, Non-small cell lung cancer
How much was the improvement?
Poor
44%
Average
33%
Excellent
22%
What were the side-effects while using Gefimipsa 250mg Capsule?
No Side Effec*
67%
Nausea
33%
*No Side Effect
How do you take Gefimipsa Capsule?
With or witho*
50%
With food
50%
*With or without food
Please rate Gefimipsa 250mg Capsule on price
Average
50%
Expensive
50%
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Chabner BA, Barnes J, Neal J, et al. Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilmanβs: The Pharmacological Basis of Therapeutics. 12th ed. New York, New York: McGraw-Hill Medical; 2011. pp. 1734-35.
- Chu E, Sartorelli AC. Cancer Chemotherapy. In: Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. 11th ed. New Delhi, India: Tata McGraw Hill Education Private Limited; 2009. pp. 954-55.
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. pp. 616-17.
- Gefitinib. Luton, Bedfordshire: AstraZeneca UK Limited; 2009 [revised 23 Apr. 2018]. [Accessed 232 Jan. 2019] (online) Available from:
- Drugs.com. Gefitinib Pregnancy and Breastfeeding Warnings. [Accessed 27 Mar. 2019] (online) Available from:
- Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. Gefitinib. [Updated 2018 Dec 3]. [Accessed 18 Feb. 2020] (online) Available from:
- Central Drugs Standard Control Organisation (CDSCO). [Accessed 27 Mar. 2019] (online) Available from:
Marketer details
Name: Ark Life Sciences Pvt Ltd
Address: # 50/1 & 2-IIIrd Floor,Yusuf Sarai, New Delhi -110016 (India)
Country of origin: India
Lab tests offered by us
Related/Popular tests
38 people viewed this recentlyMRP
βΉ1490
Inclusive of all taxes
30.0 capsules in 1 strip
SOLD OUT